Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accounts Payables: 2011-2024

Historic Accounts Payables for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to $1.2 million.

  • RedHill Biopharma's Accounts Payables fell 56.33% to $835,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $835,000, marking a year-over-year decrease of 56.33%. This contributed to the annual value of $1.2 million for FY2024, which is 64.37% down from last year.
  • As of FY2024, RedHill Biopharma's Accounts Payables stood at $1.2 million, which was down 64.37% from $3.3 million recorded in FY2023.
  • RedHill Biopharma's 5-year Accounts Payables high stood at $11.7 million for FY2021, and its period low was $1.2 million during FY2024.
  • In the last 3 years, RedHill Biopharma's Accounts Payables had a median value of $3.3 million in 2023 and averaged $2.9 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 176.12% in 2020, then tumbled by 64.37% in 2024.
  • Yearly analysis of 5 years shows RedHill Biopharma's Accounts Payables stood at $11.6 million in 2020, then grew by 0.96% to $11.7 million in 2021, then plummeted by 63.73% to $4.2 million in 2022, then decreased by 22.51% to $3.3 million in 2023, then slumped by 64.37% to $1.2 million in 2024.